Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH).
- Instead, Enanta now plans to prioritize combination approaches through out-licensing arrangements.
- The company has two NASH candidates, EDP-305 and EDP-297, in the clinic. Both drugs are FXR agonists.
- Neither candidate has done enough to persuade Enanta to continue internal development.
- Enanta is stopping the phase 2b trial of EDP-305 that began last year after an interim analysis of the 12-week data.
- Enanta had the option to switch its focus to its follow-up candidate. However, a Phase 1 trial suggested EDP-297 is "not substantially differentiated" from EDP-305.
- The phase 1 study "found the overall balance of activity and tolerability was comparable to that of EDP-305."
- Price Action: ENTA stock closed down by 1.26% at $60.19 on Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!